Browse the evidence

Discontinuation of GLP-1 therapy leads to rapid and substantial weight regain, often returning to near baseline levels within one year, highlighting the chronic nature of obesity treatment.

GLP-1 medications are not a one-time fix for obesity. If you stop taking them, you will likely regain most of the weight you lost. This suggests that obesity management with these drugs is intended to be long-term, similar to managing blood pressure or cholesterol.

GLP-1 RAs reduce Major Adverse Cardiovascular Events (MACE) by 14-20% in patients with Type 2 Diabetes and Obesity, independent of glycemic control.

GLP-1 medications significantly reduce the risk of heart attacks, strokes, and cardiovascular death in people with diabetes or obesity. This benefit exists even if blood sugar control is not the primary goal. Discuss cardiovascular risk with your doctor to see if a GLP-1 RA is appropriate.

Current pharmacological treatments for obesity, including incretin-based therapies (semaglutide, tirzepatide), result in significant skeletal muscle loss (approx. 7-10% of lean mass) alongside fat loss.

If you are using GLP-1 medications, expect to lose some muscle. You must actively combat this by eating enough protein and doing resistance training to preserve your metabolic engine.

Individuals with Type 2 Diabetes (T2D) exhibit significantly reduced cardiorespiratory fitness (CRF), measured as peak oxygen uptake (VO2peak), compared to healthy controls, with reductions averaging 13.9% for absolute VO2peak and 17.4% for relative VO2peak.

If you have Type 2 Diabetes, expect your maximum oxygen uptake to be lower than a healthy peer's, even if you feel fine. This is a physiological marker of the disease, not a lack of effort. Start exercise interventions at a lower intensity to manage early fatigue, and focus on consistency rather than high intensity initially, as improving this baseline fitness is critical for long-term health outcomes.

GLP-1 receptor agonists (GLP-1RA) are effective pharmacological interventions for obesity that work by binding to GLP-1 receptors to stimulate insulin secretion, suppress glucagon, delay gastric emptying, and reduce appetite.

GLP-1 receptor agonists are a key pharmacological tool for treating obesity. They work by mimicking a gut hormone to reduce appetite and improve metabolic function. Consult a doctor to see if this treatment is appropriate for you.

Higher BMI, particularly severe obesity (Class 2 and 3), is robustly associated with increased risk of heart failure and atrial fibrillation, independent of traditional risk factors.

Maintaining a healthy weight is critical for preventing heart failure and irregular heartbeats. Severe obesity significantly increases these risks, even if your blood pressure and cholesterol are managed. Weight management should be treated as a primary medical intervention to protect heart health.

Females with severe obesity face a disproportionately higher relative risk for stroke, total CVD, and all-cause mortality compared to males with similar obesity levels.

Women with obesity should be particularly vigilant about stroke risk, as their relative risk increases more sharply with obesity severity than men's. Regular cardiovascular screening is essential for women with higher BMI.

Ketogenic diets (≤10% carbs) produce greater weight loss but also greater increases in LDL and total cholesterol compared to moderate-carb diets (26-45% carbs).

If you choose a strict ketogenic diet (under 10% carbs), expect greater weight loss but also a significant rise in LDL and total cholesterol. If you want a balance of weight loss and heart health markers, a moderate-carb diet (26-45% carbs) might be a better choice.

Higher BMI categories, particularly Class III obesity (BMI ≥40 kg/m2), are strongly associated with worse self-reported overall health, quality of life, severe pain, fatigue, and limited physical activity, as well as an increased risk of developing chronic pain syndrome, chronic fatigue syndrome, fibromyalgia, and insomnia.

If you have obesity, do not ignore persistent pain, fatigue, or sleep issues. These are not just 'side effects' of weight but significant health risks linked to conditions like fibromyalgia and chronic fatigue. Seek medical evaluation for these symptoms, as treating them can improve your quality of life and functional ability, independent of weight loss goals.

Weekly subcutaneous semaglutide (1.0 mg) significantly reduces major adverse cardiovascular events (MACE), cardiovascular death, and all-cause death in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease.

If you have type 2 diabetes and existing heart disease, ask your doctor about GLP-1 receptor agonists like semaglutide. These medications, taken as a weekly injection, have been proven to significantly lower your risk of heart attacks, strokes, and death compared to standard treatments. This is a critical step for protecting your heart and kidneys.

Weekly subcutaneous semaglutide (1.0 mg) significantly reduces major renal events, cardiovascular death, and all-cause death in patients with type 2 diabetes and chronic kidney disease.

If you have type 2 diabetes and chronic kidney disease, ask your doctor about weekly semaglutide injections. This treatment has been shown to significantly slow the progression of kidney disease and reduce the risk of heart-related death and overall death, offering strong protection for your kidneys and heart.

SGLT2 inhibitors reduce cardiovascular death, heart failure hospitalizations, and kidney disease progression in patients with cardio-renal-metabolic syndrome, regardless of diabetes status.

If you have heart failure, chronic kidney disease, or type 2 diabetes with high cardiovascular risk, ask your doctor about SGLT2 inhibitors (like empagliflozin or dapagliflozin). These drugs protect your heart and kidneys, not just your blood sugar, and work even if you don't have diabetes. The benefits are substantial and supported by major clinical trials.

Mechanical tension is the primary and sufficient stimulus for load-induced human skeletal muscle hypertrophy, whereas acute hormonal spikes, metabolic stress, and cell swelling ('the pump') do not meaningfully contribute to the hypertrophic process.

To build muscle, prioritize mechanical tension through resistance training (lifting weights with progressive overload). Do not design your workouts around chasing a 'pump' or relying on metabolic stress (high reps, short rest) as primary drivers, as these do not add to hypertrophy beyond what mechanical tension provides. Similarly, do not expect natural acute hormonal spikes to drive growth; they are not required for hypertrophy to occur.

Childhood obesity is a strong predictor of adult obesity, with obese children being approximately five times more likely to remain obese in adulthood compared to normal-weight peers.

If your child is obese, do not wait for them to 'grow out of it.' The risk of them remaining obese into adulthood is 80%. Address dietary habits and physical activity early to prevent long-term metabolic health issues.

Obesity is a chronic, relapsing disease driven by disruptions in homeostatic, hedonic, and cognitive systems, rather than solely a lifestyle outcome, and requires multidisciplinary management including pharmacotherapy and surgery.

Treat obesity as a chronic disease, not a lifestyle failure. For eligible patients, GLP-1 agonists like semaglutide (2.4 mg weekly) combined with lifestyle changes produce significant weight loss (approx. 15%). Manage GI side effects with slow titration. Consider surgery for BMI ≥35.

Metabolic bariatric surgery is the most effective treatment for obesity across all BMI classes, offering durable weight loss and improvement in comorbidities.

For eligible patients (BMI ≥35, or 30-34.9 with failed lifestyle/pharma), metabolic bariatric surgery (sleeve or bypass) is the most effective treatment for durable weight loss and comorbidity improvement. It is recommended for BMI ≥35 regardless of comorbidities.

High-efficacy anti-obesity medications (AOMs) like semaglutide and tirzepatide produce significant weight loss in the majority of patients, but a subset of non-responders exists, and predictors of response or intolerance are currently unknown.

High-efficacy AOMs like semaglutide and tirzepatide work for most people, but not all. If you are a non-responder, it is not your fault, and current science cannot yet predict who will respond. Discuss alternative strategies or phenotypes with your provider.

GLP-1 receptor agonists (semaglutide 2.4 mg) and dual GIP/GLP-1 agonists (tirzepatide) reduce major adverse cardiovascular events (MACE) in obese patients without diabetes, independent of weight loss alone.

If you are obese and have existing heart disease, ask your doctor about GLP-1 agonists like semaglutide. They significantly lower your risk of heart attack and stroke, offering protection beyond just weight loss.

GLP-1 and GIP/GLP-1 agonists improve heart failure with preserved ejection fraction (HFpEF) symptoms and functional capacity in obese patients, independent of diabetes status.

If you have obesity and heart failure with preserved ejection fraction, discuss GLP-1 agonists with your cardiologist. They can significantly improve your heart failure symptoms, exercise capacity, and quality of life.

GLP-1 and GIP receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease, independent of weight loss magnitude.

For patients with type 2 diabetes and existing heart disease, GLP-1 therapies like liraglutide and semaglutide significantly reduce the risk of major cardiovascular events (heart attack, stroke, cardiovascular death). This benefit exists alongside weight loss and may be partly due to direct protective effects on the heart and blood vessels. These drugs are now a standard part of care for high-risk diabetic patients.

SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce cardiovascular death, heart failure hospitalizations, and renal composite outcomes in patients with type 2 diabetes and chronic kidney disease, regardless of baseline glycemic control.

If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors like empagliflozin or dapagliflozin. These medications are proven to significantly lower your risk of heart failure, kidney failure, and death, offering protection beyond just blood sugar control.

GLP-1 receptor agonists (liraglutide, semaglutide) reduce major adverse cardiovascular events (MACE) and nephropathy progression in high-risk patients with Type 2 Diabetes.

For those with Type 2 Diabetes and high heart risk, GLP-1 agonists like liraglutide or semaglutide offer strong protection against heart attacks and strokes, as well as kidney damage. Discuss these options with your doctor, especially if you are overweight.

SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) significantly reduce cardiovascular mortality and heart failure hospitalizations in patients with type 2 diabetes and established cardiovascular disease, independent of glycemic control.

If you have Type 2 Diabetes and heart disease or high risk, ask your doctor about SGLT-2 inhibitors (like empagliflozin or dapagliflozin). These drugs protect your heart and kidneys beyond just lowering blood sugar, significantly reducing the risk of heart failure hospitalization and death. Be aware of potential side effects like infections, but discuss how the heart benefits may outweigh these risks for your specific health profile.

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) reduce Major Adverse Cardiovascular Events (MACE) and all-cause mortality in patients with Type 2 Diabetes and established CVD, primarily through weight loss, blood pressure reduction, and anti-inflammatory effects.

If you have Type 2 Diabetes and heart disease, GLP-1 agonists (like semaglutide or liraglutide) are highly effective at reducing the risk of heart attacks, strokes, and death. They work by mimicking a gut hormone to lower blood sugar, promote weight loss, and reduce blood pressure. While they require injections and may cause temporary stomach issues, the heart protection benefits are substantial and well-documented.